Pfizer's bone drug may cause deaths, FDA analysis reports

09/4/2008 | Washington Post, The

Women who got low doses of Pfizer's Fablyn -- a drug candidate for osteoporosis -- were more likely to die within five years compared with those who received placebo, according to an analysis from FDA staff. Reviewers said the once-daily pill is effective for averting fractures in postmenopausal women with osteoporosis, but they are concerned that patients on Fablyn had more than twice the risk of developing blood clots. A panel of independent advisers is scheduled Monday to review the drug's safety.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI